In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections.

@article{Miyazaki2001InVA,
  title={In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections.},
  author={Soichiro Miyazaki and Tohru Hosoyama and Nobuhiko Furuya and Yoshikazu Ishii and Tetsuya Matsumoto and Akira Ohno and Kazuhiro Tateda and Keizo Yamaguchi},
  journal={Antimicrobial agents and chemotherapy},
  year={2001},
  volume={45 1},
  pages={203-7}
}
L-084 (a prodrug of LJC 11,036 [L-036]) is a new oral carbapenem. Here we compared the in vitro and in vivo antibacterial activities of L-036 with those of imipenem, faropenem, ceditoren-pivoxil, cefdinir, amoxicillin, and levofloxacin. The MICs at which 90% of the isolates were inhibited of L-036 against methicillin-susceptible staphylococci, Streptococcus pneumoniae including penicillin-resistant organisms, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae including ampicillin… CONTINUE READING
8 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…